About file location

As the EGA is co-managed by the EMBL-EBI and CRG, files could be located in the UK and/or Spain, as indicated by their respective flags.

Alternatively, files could be located in one of the international Federated EGA nodes, as indicated next to the node's flag.
Need Help?

Clinical Outcomes by Tumor Mutational Burden and Inflammatory Gene Expression With Combined Nivolumab and Ipilimumab or Monotherapy in Advanced Melanoma_CM67-RNASeq

Purpose Exploratory analyses of CheckMate 066 and 067 trials were conducted to investigate associations of tumor mutational burden (TMB), a 4-gene inflammatory gene expression signature, and BRAF mutation status with tumor response, progression-free survival (PFS), and overall survival (OS) in patients with advanced melanoma. Patients and Methods Patients with known programmed death ligand 1 (PD-L1) expression and BRAF mutation status received nivolumab (NIVO) or dacarbazine in CheckMate 066 and either NIVO, ipilimumab (IPI), or NIVO+IPI in CheckMate 067. Whole exome sequencing and RNA sequencing were used to determine TMB and inflammatory gene expression signature scores, respectively. These biomarkers were evaluated in terms of their association with PFS and OS. Results In the NIVO, NIVO+IPI, and IPI arms of CheckMate 067, longer survival was associated with high (> median) versus low (≤ median) TMB with hazard ratios (HRs) (95% confidence interval [CI]) for PFS of 0.45 (0.30–0.65), 0.55 (0.38–0.81), and 0.60 (0.43–0.82), and for OS of 0.46 (0.30–0.71), 0.53 (0.34–0.82), and 0.52 (0.36–0.74), respectively. For NIVO-treated patients, these results were confirmed in CheckMate 066. A survival benefit was observed with high TMB and absence of BRAF mutation. Survival was associated with high versus low inflammatory signature scores with HRs (95% CI) for PFS of 0.56 (0.34–0.94), 0.40 (0.23–0.72), and 0.43 (0.27–0.70), and for OS of 0.37 (0.20–0.66), 0.38 (0.19–0.74), and 0.46 (0.27–0.79), in the NIVO, NIVO+IPI, and IPI arms, respectively. Weak correlations were observed between PD-L1, TMB, and the inflammatory signature. Conclusions Combined assessment of TMB, inflammatory gene expression signature, and BRAF mutation status may be predictive for response to immunotherapy in advanced melanoma.

Request Access

DUO:0000006
version: 2019-01-07

health or medical or biomedical research

This data use permission indicates that use is allowed for health/medical/biomedical purposes; does not include the study of population origins or ancestry.

DUO:0000007
version: 2019-01-07

disease specific research

This data use permission indicates that use is allowed provided it is related to the specified disease.

ModifiersMONDO:0004992 MONDO:0005105

Requests for access the BMS accession numbers in EGA should be directed to the BMS FastTrack portal - https://fasttrack.bms.com/. This externally facing website serves as BMS’ request portal for all ISRs (both clinical and non-clinical), as well as for requests for data generated as a part of a BMS study. This portal is facilitated by BMS’ Clinical Trial Transparency organization.

Purpose Below you will find general notes and tips for when you are creating an ISR Request. General Notes and Tips • * [Asterisks] indicate a required field within the interface • You will not be able to move on to the next page if a required field is not completed • Periodically click Save (located at the bottom right corner on any form) in order to save your information. If you do not have all the information, which is necessary to submit your request, click Save and a draft will be available for you on your homepage when you are ready to return to the form. The forms do not auto-save. • FastTrack has a security time-out feature. After sixty (60) minutes of inactivity, you will be required to log back into the system. o If you are working on a record and leave it open while performing other tasks, it is recommend that you navigate to the bottom of the record and click Save to prevent you from losing data you have entered • You can return to any section of the form at any point by clicking the tabs at the top of the page or clicking Back in the lower left of the page We are committed to providing you with answers to your questions and concerns. Please contact us using the information below, and we will respond to your inquiry as quickly as possible. Technical Support Main Number: +1 844-439-5499 (US only) For Outside US, please see the “International BMS Help Desk Phone Number Guide” Main Email: hd-sci-apps@bms.com

Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.

Study ID Study Title Study Type
EGAS00001004564 Other

This table displays only public information pertaining to the files in the dataset. If you wish to access this dataset, please submit a request. If you already have access to these data files, please consult the download documentation.

ID File Type Size Quality Report
Located in
i
EGAF00004186583 fastq.gz 2.1 GB Report
EGAF00004186584 fastq.gz 2.2 GB Report
EGAF00004186585 fastq.gz 2.5 GB Report
EGAF00004186586 fastq.gz 2.6 GB Report
EGAF00004186587 fastq.gz 2.5 GB Report
EGAF00004186588 fastq.gz 2.6 GB Report
EGAF00004186589 fastq.gz 2.4 GB Report
EGAF00004186590 fastq.gz 2.5 GB Report
EGAF00004186591 fastq.gz 2.4 GB Report
EGAF00004186592 fastq.gz 2.5 GB Report
EGAF00004186593 fastq.gz 2.2 GB Report
EGAF00004186594 fastq.gz 2.3 GB Report
EGAF00004186595 fastq.gz 1.9 GB Report
EGAF00004186596 fastq.gz 2.1 GB Report
EGAF00004186597 fastq.gz 2.1 GB Report
EGAF00004186598 fastq.gz 2.3 GB Report
EGAF00004186599 fastq.gz 2.2 GB Report
EGAF00004186600 fastq.gz 2.3 GB Report
EGAF00004186601 fastq.gz 2.4 GB Report
EGAF00004186602 fastq.gz 2.5 GB Report
EGAF00004186603 fastq.gz 2.3 GB Report
EGAF00004186604 fastq.gz 2.4 GB Report
EGAF00004186605 fastq.gz 2.3 GB Report
EGAF00004186606 fastq.gz 2.4 GB Report
EGAF00004186607 fastq.gz 2.7 GB Report
EGAF00004186608 fastq.gz 2.8 GB Report
EGAF00004186609 fastq.gz 2.9 GB Report
EGAF00004186610 fastq.gz 3.1 GB Report
EGAF00004186611 fastq.gz 2.1 GB Report
EGAF00004186612 fastq.gz 2.2 GB Report
EGAF00004186613 fastq.gz 2.0 GB Report
EGAF00004186614 fastq.gz 2.1 GB Report
EGAF00004186615 fastq.gz 2.1 GB Report
EGAF00004186616 fastq.gz 2.2 GB Report
EGAF00004186617 fastq.gz 2.7 GB Report
EGAF00004186618 fastq.gz 2.9 GB Report
EGAF00004186619 fastq.gz 2.0 GB Report
EGAF00004186620 fastq.gz 2.2 GB Report
EGAF00004186621 fastq.gz 2.1 GB Report
EGAF00004186622 fastq.gz 2.3 GB Report
EGAF00004186623 fastq.gz 2.3 GB Report
EGAF00004186624 fastq.gz 2.4 GB Report
EGAF00004186625 fastq.gz 2.9 GB Report
EGAF00004186626 fastq.gz 3.2 GB Report
EGAF00004186627 fastq.gz 2.6 GB Report
EGAF00004186628 fastq.gz 2.7 GB Report
EGAF00004186629 fastq.gz 2.3 GB Report
EGAF00004186630 fastq.gz 2.5 GB Report
EGAF00004186631 fastq.gz 3.4 GB Report
EGAF00004186632 fastq.gz 3.5 GB Report
EGAF00004186633 fastq.gz 2.7 GB Report
EGAF00004186634 fastq.gz 2.8 GB Report
EGAF00004186635 fastq.gz 2.5 GB Report
EGAF00004186636 fastq.gz 2.6 GB Report
EGAF00004186637 fastq.gz 2.6 GB Report
EGAF00004186638 fastq.gz 2.7 GB Report
EGAF00004186639 fastq.gz 2.4 GB Report
EGAF00004186640 fastq.gz 2.6 GB Report
EGAF00004186641 fastq.gz 2.3 GB Report
EGAF00004186642 fastq.gz 2.4 GB Report
EGAF00004186643 fastq.gz 2.4 GB Report
EGAF00004186644 fastq.gz 2.5 GB Report
EGAF00004186645 fastq.gz 2.5 GB Report
EGAF00004186646 fastq.gz 2.6 GB Report
EGAF00004186647 fastq.gz 2.6 GB Report
EGAF00004186648 fastq.gz 2.6 GB Report
EGAF00004186649 fastq.gz 2.6 GB Report
EGAF00004186650 fastq.gz 2.6 GB Report
EGAF00004186651 fastq.gz 2.4 GB Report
EGAF00004186652 fastq.gz 2.4 GB Report
EGAF00004186653 fastq.gz 2.7 GB Report
EGAF00004186654 fastq.gz 2.8 GB Report
EGAF00004186655 fastq.gz 2.7 GB Report
EGAF00004186656 fastq.gz 2.8 GB Report
EGAF00004186657 fastq.gz 2.9 GB Report
EGAF00004186658 fastq.gz 3.0 GB Report
76 Files (190.0 GB)